Gastroenterology Flashcards
What is Budd-Chiari syndrome?
Thrombotic or non-thrombotic obstruction of the hepatic venous outflow leading to (HAP):
- Hepatomegaly
- Ascites
- Pain in abdomen
True/False: aortic stenosis (AS) is associated with angiodysplasia, treatment of AS leads to regression of angiodysplasia.
True.
Which of the following treatments for ‘achalasia’ is best for symptom relief?
A. Medications (CCB, nitrates) to relax LOS
B. Surgical procedure (e.g. Heller myotomy)
C. Nissen fundoplication
D. Botox to the LOS
NB: LOS = lower oesophageal sphincter
A. Variable effect and with adverse effects
B. Best option - greater that 80% success with more than a year of persistent benefit
C. Used in conjunction with myotomy to alleviate the reflux that occurs from myotomy
D. Short-lived effect
What are the 4 risk factors for hepatotoxicity during a paracetamol overdose?
- Malnourished (anorexia/bulimia nervosa)
- Drugs that induce CYP3A4
- ‘Chronic’ EtOH abuse (not acute intake)
- HIV positive
Patient is obese with a diagnosis of NASH, what a simple intervention that will improve liver histology?
Weight-loss
Which of the following is a live vaccine and therefore should NOT be given in an immunosuppressed patient:
A. Infuenza B. Conjugated meningococcal C. Varicella/Zoster D. Conjugated Pneumococcal E. Hepatitis A
C. Varicella Zoster
What is the most common cause of severe B12 deficiency worldwide?
Pernicious anaemia
What is the pernicious anaemia?
- Autoimmune gastritis due to destruction of gastric parietal cells and associated lack of intrinsic factor binding to vitamin B12.
- Immune response directed at gastric H+/K+-ATPase which leads to achlorhydria
Regarding Rifaximin:
- MOA
- Indications
- MOA = inhibits bacterial RNA polymerase
- Used in prevention of encephalopathy in end-stage liver disease - reduces hospitalisations and maintains remission from encephalopathy.
T/F: Rifaximin is more effective at maintaining remission from encephalopathy in end-stage liver disease than non-absorbable dissacharides.
True
What are the risk factors for developing Barret’s oesophagus?
- Smoking
- Central obesity
- Caucasian
- Fhx in 1st degree relative
‘white smoking fat bloke whose brother had Barret’s oesophagus’ - Homer Simpson / Bart
T/F: alcohol consumption is a risk factor for developing Barret’s oesophagus.
False.
Which cells in the GIT secrete the following hormones:
- Gastrin
- CCK
- Secretin
- Somatostatin
- Gastrin = G-cells
G for Gastrin - CCK = I-cells
I love hot ChiCKs - Secretin = S-cells
Secret Secretary - Somatostatin = D-cells
1’m SO Drunk
What is the definition of functional dyspepsia?
Rome III criteria require more than one of the following:
- postprandial fullness
- early satiation
- epigastric pain or burning
AND with no evidence of structural disease (including at upper endoscopy) to explain the symptoms
AND need symptoms for 3 month duration
Elderly patient presents with active haematemesis and malaena and is noted to be haemodynamically unstable.
- Within what timeframe should endoscopy be performed?
- Do PPI infusions reduce blood transfusion requirements in peptic ulcer bleeds?
- What is the utility of give the patient IV erythromycin?
- What prognostic score predicts risk of re-bleeding and mortality?
- Within what timeframe should endoscopy be performed?
24h - Do PPI infusions reduce blood transfusion requirements in peptic ulcer bleeds?
Yes - What is the utility of give the patient IV erythromycin?
Promotes gastric emptying and therefore improves endoscopic visualisation.
4. What prognostic score predicts risk of re-bleeding and mortality? Rockall score (Age above 80, BP below 100, HR above 100, IHD)
Patient with following serology:
HBsAb positive
HBcAB negative
Diagnosis?
Previous HBV vaccination
What is the timeframe for post-exposure prophylaxis in HIV?
72h
Cholestatic LFTs, p-ANCA positive, anti-mitochondrial antibody (AMA) positive.
What is the diagnosis?
Primary Biliary Cirrhosis (PBC)
P for p-ANCA
B for BAMA (i.e. AMA)
C for cholestatic LFTs
You suspect patient with CRC has Lynch syndrome, what test do you ask for first?
IHC for MMR genes
Patient with CRC is investigated for Lynch syndrome with IHC for MMR gene which is noted to be negative.
What is the next test?
No further testing unless patient has a strong clinical history
Patient with CRC is investigated for Lynch syndrome with IHC for MMR gene which is noted to be positive.
What test would be nest in the following scenarios:
- Absent MLH1 / PMS2 protein expression
- Absent MSH2 / MSH6 protein expression
- All proteins present
- Absent MLH1 / PMS2 protein expression
BRAF V600E mutation analysis - Absent MSH2 / MSH6 protein expression
Germline mutational analysis - All proteins present
No further testing
Patient with CRC is investigated for Lynch syndrome with a positive IHC for MMR gene, absent MLH1 / PMS2 protein expression and negative BRAF V600E mutation.
What test should be consider next?
Germline mutational analysis
Patient with CRC is investigated for Lynch syndrome with a positive IHC for MMR gene, absent MLH1 / PMS2 protein expression and positive BRAF V600E mutation.
What test should be consider next?
No further testing
Patient X with CRC positive with:
- Positive IHC for MMR gene
- Absent MLH1 / PMS2 protein expression
- Negative BRAF V600E mutation
Patient has germline mutational analysis - what are the 2 possible outcomes?
- MSI (microsatellite instability) = Lynch syndrome
2. MSS (microsatellite stability) = Familial CRC type X
Patient Y with CRC positive with:
- Positive IHC for MMR gene
- Absent MSH2 / MSH6 protein expression
Patient has germline mutational analysis - what are the 2 possible outcomes?
- MSI (microsatellite instability) = Lynch syndrome
2. MSS (microsatellite stability) = Familial CRC type X
What are the 3 genotypes associated with Lynch syndrome?
MLH1
MSH2
MSH6
T/F: Patient co-infected to HIV-1 and HCV have higher rates hepatic decompensation, liver cirrhosis, HCC and death.
True
T/F: Patient co-infected with HIV-1 and HCV genotypes 2 and 3 have high rates of virological response with 12 weeks of treatment with Ledipasvir and Sofobuvir.
False - wrong HCV genotypes
Patient co-infected with HIV-1 and HCV genotypes 1 and 4 have high rates of virological response with 12 weeks of treatment with Ledipasvir and Sofobuvir.
Once daily Sofosbuvir-velpatasvir for 12 weeks provides high rate of sustained virological response among both treated and untreated patients, including compensated cirrhotics, affected by which HCV genotypes?
HCV genotype 1, 2, 4, 5 or 6.
For autoimmune hepatitis:
- Which sex is more likely to get it?
- Which ethnicity is more likely to progress to cirrhosis?
- Which sex is more likely to get it?
Female - Which ethnicity is more likely to progress to cirrhosis?
African Americans
Which of the 2 types of autoimmune hepatitis (AH) is more likely to be severe?
Type 1 AH - variable severity
Type 2 AH - always severe
What are the 4 autoantibodies found in type 1 autoimmune hepatitis (AH)?
ANCA
Anti-smooth muscle Abs
Soluble liver Ag
Soluble liver/pancreas Ag
What are the 4 autoantibodies found in type 2 autoimmune hepatitis (AH)?
Anti-liver kidney microsomal Ab Type 1 and 3
Anti-liver-cytosol Ab type 1
T/F: Autoimmune hepatitis (AH) is associated with hypergammaglobulinaemia.
True
What is the typical histopathology of autoimmune hepatitis (AH)?
- Infiltration of lymphocytes and plasma cells extending from the portal tract to surrounding parenchyma.
- ‘Interface hepatitis’ - sharp difference between normal parenchyma and inflammatory zone
Which biochemical and histopathological feature suggests that an autoimmune hepatitis (AH) should be treated?
What is the treatment?
Is the condition likely to relapse with withdrawal of treatment?
Indications for treatment:
- Elevated aminotransferase more than 2x upper limit
- Interface hepatitis on biopsy
Treatment:
Steroids and AZA +/- liver transplant if unresponsive (esp. Type 2 AH)
Relapsing disease is common if treatment is withdrawn.
T/F: Formal diagnosis of coeliacs disease requires a duodenal biopsy.
True
All patients about to undergo chemotherapy or immunosuppression should be screened with HBsAg and anti-HBc.
Patient is seronegative for HBV. What is recommended?
HBV vaccination
All patients about to undergo chemotherapy or immunosuppression should be screened with HBsAg and anti-HBc.
Patient is HBaAg positive. What is recommended?
- Test for HBV DNA levels
- Start NA (nucleoside analogues) pre-emptively regardless of HBV DNA levels
- Continue for 12m post cessation of therapy (i.e. chemo or immunosuppression)
All patients about to undergo chemotherapy or immunosuppression should be screened with HBsAg and anti-HBc.
Patient is HBsAG negative, anti-HBc positive with detectable HBV DNA. What is recommended?
SAME as for HBsAg positive patients:
- Test for HBV DNA levels
- Start NA (nucleoside analogues) pre-emptively regardless of HBV DNA levels
- Continue for 12m post cessation of therapy (i.e. chemo or immunosuppression)
Patient is HBsAG negative, anti-HBc positive with UNDETECTABLE HBV DNA. What is recommended?
- Regardless of HBsAb status (i.e. immunity) should be monitored closely with ALT and HBV DNA.
- NA (nucleoside analogues) to be commenced if HBV DNA is positive even if ALT is NOT elevated.
What is the MOA lamivudine?
Antiretroviral - analogue of cytadine